First patient infected by tick-borne encephalitis virus For the first time, a person in the Netherlands has fallen ill after a bite from a tick carrying the tick-borne encephalitis virus (TBE virus).
RIVM and German BfR enter cooperation agreement on animal protection and food safety The German Federal Institute of Risk Assessment (BfR) and the Dutch National Institute for Public Health and the Environment, RIVM have signed a cooperation agreement, focused on developing new sci
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
More tobacco products, number of additives stable In 2014, the number of tobacco products on the Dutch market increased to 4212. This is a 5 percent increase compared to 2013.
Breakthrough on cumulative risk assessment exposure to pesticides in food The European Commission, Member States and EFSA have taken a major step forward in their work on assessing the cumulative risks from exposure to pesticides in food.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
RIVM Nutrition and Food Safety expert gets top risk assessment function at EFSA As of November 1, Prof. Hans Verhagen will join the European Food Safety Authorithy (EFSA) in Parma, Italy as Head of the Risk Assessment and Scientific Assistance Department (RASA).
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.